Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：436頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2014’, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2014’, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 10
Global Markets Direct Report Coverage 10
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview 11
Therapeutics Development 12
Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview 12
Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis 13
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies 14
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 20
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies 26
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes 31
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development 32
Bristol-Myers Squibb Company 32
Johnson & Johnson 33
Sanofi 34
GlaxoSmithKline plc 35
Seattle Genetics, Inc. 36
MedImmune, LLC 37
medac GmbH 38
Merck & Co., Inc. 39
Gamida Cell Ltd. 40
Bio-Path Holdings, Inc. 41
Millennium Pharmaceuticals, Inc. 42
Novartis AG 43
Pfizer Inc. 44
Astex Pharmaceuticals, Inc. 45
Onyx Pharmaceuticals, Inc. 46
Incyte Corporation 47
4SC AG 48
Immunomedics, Inc. 49
Ariad Pharmaceuticals, Inc. 50
OncoVista Innovative Therapies, Inc. 51
Jazz Pharmaceuticals plc 52
Portola Pharmaceuticals, Inc. 53
Mundipharma International Limited 54
MorphoSys AG 55
Threshold Pharmaceuticals, Inc. 56
Synta Pharmaceuticals Corp. 57
Sareum Holdings plc 58
SymBio Pharmaceuticals Limited 59
Oryzon Genomics S.A. 60
Spectrum Pharmaceuticals, Inc. 61
Ambit Biosciences Corporation 62
Abiogen Pharma S.p.A. 63
ERYtech Pharma 64
Celator Pharmaceuticals, Inc. 65
Aileron Therapeutics, Inc. 66
TetraLogic Pharmaceuticals 67
CanBas Co., Ltd. 68
Deciphera Pharmaceuticals, LLC 69
Onconova Therapeutics, Inc. 70
Effimune SAS 71
Kainos Medicine, Inc. 72
Polyphor Ltd. 73
Syndax Pharmaceuticals, Inc. 74
Omeros Corporation 75
SBI Biotech Co., Ltd. 76
Kiadis Pharma B.V. 77
Bellicum Pharmaceuticals, Inc. 78
Sigma-Tau Pharmaceuticals, Inc 79
Interprotein Corporation 80
EpiZyme, Inc. 81
NuCana BioMed Limited 82
Pfenex Inc. 83
Otsuka Holdings Co., Ltd. 84
Bexion Pharmaceuticals, LLC. 85
Karyopharm Therapeutics, Inc. 86
International Biotechnology Center Generium 87
Rhizen Pharmaceuticals SA 88
ARA Healthcare Pvt. Ltd. 89
Cantargia AB 90
Formula Pharmaceuticals, Inc. 91
AbbVie Inc. 92
Amgen Astellas BioPharma K.K. 93
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment 94
Assessment by Monotherapy Products 94
Assessment by Combination Products 95
Assessment by Target 96
Assessment by Mechanism of Action 101
Assessment by Route of Administration 107
Assessment by Molecule Type 109
Drug Profiles 112
ponatinib - Drug Profile 112
calaspargase pegol - Drug Profile 114
StemEx - Drug Profile 115
blinatumomab - Drug Profile 117
asparaginase - Drug Profile 120
vincristine sulfate liposomal - Drug Profile 122
inotuzumab ozogamicin - Drug Profile 125
Recombinant asparaginase - Drug Profile 127
asparaginase - Drug Profile 128
SAR-3419 - Drug Profile 129
moxetumomab pasudotox - Drug Profile 131
brentuximab vedotin - Drug Profile 133
ponatinib - Drug Profile 138
ATIR - Drug Profile 140
forodesine hydrochloride - Drug Profile 141
MOR-208 - Drug Profile 143
epratuzumab - Drug Profile 144
CTL-019 - Drug Profile 149
Iodine I-131 Monoclonal Antibody BC8 + [cyclophosphamide] + [fludarabine phosphate] + [mycophenolate mofetil] + [tacrolimus] + Allogeneic Bone Marrow Transplantation + Radiation Therapy - Drug Profile 151
glasdegib - Drug Profile 152
FPI-01 - Drug Profile 154
veltuzumab - Drug Profile 156
ponatinib - Drug Profile 159
lonafarnib - Drug Profile 161
ruxolitinib phosphate - Drug Profile 163
OVI-123 - Drug Profile 167
rigosertib sodium - Drug Profile 168
CD19CAR/Virus Specific T Cells - Drug Profile 171
birinapant - Drug Profile 172
BPX-501 - Drug Profile 174
Allogeneic CD19CAR-TCM cells - Drug Profile 176
Autologous CD19 CAR + EGFTt + T Cells - Drug Profile 177
DFP-10917 - Drug Profile 178
CD25/71 Allodepleted Donor T cells - Drug Profile 179
CD19 Transduced EBV-CTL - Drug Profile 180
Minor Histocompatibility Antigen - Drug Profile 181
ORY-1001 - Drug Profile 182
entinostat - Drug Profile 184
pevonedistat hydrochloride - Drug Profile 187
SGN-CD19A - Drug Profile 190
panobinostat - Drug Profile 191
4SC-202 - Drug Profile 197
AT-9283 - Drug Profile 199
SAR-650984 - Drug Profile 201
carfilzomib - Drug Profile 203
everolimus - Drug Profile 205
asparaginase - Drug Profile 210
ganetespib - Drug Profile 212
TH-302 - Drug Profile 216
(cytarabine + daunorubicin) - Drug Profile 223
quizartinib - Drug Profile 225
briciclib sodium - Drug Profile 227
ciclopirox olamine - Drug Profile 228
Combotox - Drug Profile 229
PF-03084014 - Drug Profile 230
BP-100-1.01 - Drug Profile 231
rebastinib tosylate - Drug Profile 233
GNKG-168 - Drug Profile 235
ilorasertib - Drug Profile 237
OPB-51602 - Drug Profile 239
BMS-906024 - Drug Profile 240
Anti-CD19-CAR-Transduced T Cells - Drug Profile 241
KPT-330 - Drug Profile 242
EPZ-5676 - Drug Profile 244
TGR-1202 - Drug Profile 245
Asparec - Drug Profile 246
SyB-0702 - Drug Profile 248
MD-707 - Drug Profile 249
serdemetan - Drug Profile 250
CBS-9106 - Drug Profile 252
Aurora + FLT3 Kinase Programme - Drug Profile 254
ARABS-1 - Drug Profile 255
IPC-003 - Drug Profile 256
Interleukin-1 Receptor Associated Protein Targeting Antibody - Drug Profile 257
Lenaldekar - Drug Profile 258
BXQ-350 - Drug Profile 259
Mastermind Coactivator Protein Derived Stapled Peptides - Drug Profile 261
BLyS-Gelonin Fusion Toxin - Drug Profile 262
PRT-060318 - Drug Profile 263
UNC-569 - Drug Profile 264
Small Molecule to Inhibit Mer Receptor Tyrosine Kinase for Oncology - Drug Profile 266
Mer Antibody - Drug Profile 268
Small molecules for Oncology - Drug Profile 269
GNR-022 - Drug Profile 270
MSK-777 - Drug Profile 271
CB-839 - Drug Profile 273
NUC-5435 - Drug Profile 274
pegaspargase biosimilar - Drug Profile 275
Drugs to Inhibit Gamma-Secretase for Acute Lymphocytic Leukemia - Drug Profile 276
BMS-871 - Drug Profile 277
KM-101 - Drug Profile 278
ABT-737 - Drug Profile 279
Tyrosine Kinase2 Program - Drug Profile 281
P2Y8 Antagonist for Acute Lymphoblastic Leukemia - Drug Profile 282
Turbostatin-1 - Drug Profile 283
Turbostatin-2 - Drug Profile 284
Turbostatin-3 - Drug Profile 285
Turbostatin-4 - Drug Profile 286
Drugs Targeting Tyrosine Kinase 2 - Drug Profile 287
Small Molecules to Inhibit JAK for Oncology and Hematological Disorders - Drug Profile 288
POL-5551 - Drug Profile 289
CRLF-2 Inhibitors - Drug Profile 291
KM-201 - Drug Profile 292
Asparec - Drug Profile 293
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Recent Pipeline Updates 295
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects 413
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products 414
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones 415
Featured News & Press Releases 415
Appendix 428
Methodology 428
Coverage 428
Secondary Research 428
Primary Research 428
Expert Panel Validation 428
Contact Us 429
Disclaimer 429
List of Tables
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2014 19
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H1 2014 20
Number of Products under Development by Companies, H1 2014 22
Number of Products under Development by Companies, H1 2014 (Contd..1) 23
Number of Products under Development by Companies, H1 2014 (Contd..2) 24
Number of Products under Development by Companies, H1 2014 (Contd..3) 25
Number of Products under Development by Companies, H1 2014 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Comparative Analysis by Late Stage Development, H1 2014 29
Comparative Analysis by Clinical Stage Development, H1 2014 30
Comparative Analysis by Early Stage Development, H1 2014 31
Comparative Analysis by Unknown Stage Development, H1 2014 32
Products under Development by Companies, H1 2014 33
Products under Development by Companies, H1 2014 (Contd..1) 34
Products under Development by Companies, H1 2014 (Contd..2) 35
Products under Development by Companies, H1 2014 (Contd..3) 36
Products under Development by Companies, H1 2014 (Contd..4) 37
Products under Investigation by Universities/Institutes, H1 2014 38
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2014 39
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Johnson & Johnson, H1 2014 40
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sanofi, H1 2014 41
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by GlaxoSmithKline plc, H1 2014 42
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H1 2014 43
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by MedImmune, LLC, H1 2014 44
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by medac GmbH, H1 2014 45
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Merck & Co., Inc., H1 2014 46
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gamida Cell Ltd., H1 2014 47
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H1 2014 48
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 49
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Novartis AG, H1 2014 50
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfizer Inc., H1 2014 51
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 52
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 53
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Incyte Corporation, H1 2014 54
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H1 2014 55
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Immunomedics, Inc., H1 2014 56
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2014 57
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoVista Innovative Therapies, Inc., H1 2014 58
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jazz Pharmaceuticals plc, H1 2014 59
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 60
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Mundipharma International Limited, H1 2014 61
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by MorphoSys AG, H1 2014 62
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 63
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Synta Pharmaceuticals Corp., H1 2014 64
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sareum Holdings plc, H1 2014 65
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by SymBio Pharmaceuticals Limited, H1 2014 66
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oryzon Genomics S.A., H1 2014 67
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 68
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ambit Biosciences Corporation, H1 2014 69
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Abiogen Pharma S.p.A., H1 2014 70
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ERYtech Pharma, H1 2014 71
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celator Pharmaceuticals, Inc., H1 2014 72
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Aileron Therapeutics, Inc., H1 2014 73
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by TetraLogic Pharmaceuticals., H1 2014 74
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CanBas Co., Ltd., H1 2014 75
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2014 76
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Onconova Therapeutics, Inc., H1 2014 77
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Effimune SAS, H1 2014 78
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kainos Medicine, Inc., H1 2014 79
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Polyphor Ltd., H1 2014 80
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Syndax Pharmaceuticals, Inc., H1 2014 81
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Omeros Corporation, H1 2014 82
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by SBI Biotech Co., Ltd., H1 2014 83
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kiadis Pharma B.V., H1 2014 84
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2014 85
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H1 2014 86
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Interprotein Corporation, H1 2014 87
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by EpiZyme, Inc., H1 2014 88
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NuCana BioMed Limited, H1 2014 89
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfenex Inc., H1 2014 90
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 91
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bexion Pharmaceuticals, LLC., H1 2014 92
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 93
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by International Biotechnology Center Generium, H1 2014 94
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 95
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ARA Healthcare Pvt. Ltd., H1 2014 96
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cantargia AB, H1 2014 97
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H1 2014 98
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc., H1 2014 99
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 100
Assessment by Monotherapy Products, H1 2014 101
Assessment by Combination Products, H1 2014 102
Number of Products by Stage and Target, H1 2014 105
Number of Products by Stage and Mechanism of Action, H1 2014 110
Number of Products by Stage and Route of Administration, H1 2014 115
Number of Products by Stage and Molecule Type, H1 2014 118
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics - Recent Pipeline Updates, H1 2014 302
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H1 2014 420
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, H1 2014 421
List of Figures
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2014 19
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H1 2014 20
Number of Products under Development by Companies, H1 2014 21
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Comparative Analysis by Late Stage Development, H1 2014 29
Comparative Analysis by Clinical Stage Development, H1 2014 30
Comparative Analysis by Early Stage Products, H1 2014 31
Assessment by Monotherapy Products, H1 2014 101
Assessment by Combination Products, H1 2014 102
Number of Products by Top 10 Target, H1 2014 103
Number of Products by Stage and Top 10 Target, H1 2014 104
Number of Products by Top 10 Mechanism of Action, H1 2014 108
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 109
Number of Products by Top 10 Route of Administration, H1 2014 114
Number of Products by Stage and Top 10 Route of Administration, H1 2014 115
Number of Products by Top 10 Molecule Type, H1 2014 116
Number of Products by Stage and Top 10 Molecule Type, H1 2014 117
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 10
Global Markets Direct Report Coverage 10
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview 11
Therapeutics Development 12
Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview 12
Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis 13
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies 14
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 20
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies 26
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes 31
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development 32
Bristol-Myers Squibb Company 32
Johnson & Johnson 33
Sanofi 34
GlaxoSmithKline plc 35
Seattle Genetics, Inc. 36
MedImmune, LLC 37
medac GmbH 38
Merck & Co., Inc. 39
Gamida Cell Ltd. 40
Bio-Path Holdings, Inc. 41
Millennium Pharmaceuticals, Inc. 42
Novartis AG 43
Pfizer Inc. 44
Astex Pharmaceuticals, Inc. 45
Onyx Pharmaceuticals, Inc. 46
Incyte Corporation 47
4SC AG 48
Immunomedics, Inc. 49
Ariad Pharmaceuticals, Inc. 50
OncoVista Innovative Therapies, Inc. 51
Jazz Pharmaceuticals plc 52
Portola Pharmaceuticals, Inc. 53
Mundipharma International Limited 54
MorphoSys AG 55
Threshold Pharmaceuticals, Inc. 56
Synta Pharmaceuticals Corp. 57
Sareum Holdings plc 58
SymBio Pharmaceuticals Limited 59
Oryzon Genomics S.A. 60
Spectrum Pharmaceuticals, Inc. 61
Ambit Biosciences Corporation 62
Abiogen Pharma S.p.A. 63
ERYtech Pharma 64
Celator Pharmaceuticals, Inc. 65
Aileron Therapeutics, Inc. 66
TetraLogic Pharmaceuticals 67
CanBas Co., Ltd. 68
Deciphera Pharmaceuticals, LLC 69
Onconova Therapeutics, Inc. 70
Effimune SAS 71
Kainos Medicine, Inc. 72
Polyphor Ltd. 73
Syndax Pharmaceuticals, Inc. 74
Omeros Corporation 75
SBI Biotech Co., Ltd. 76
Kiadis Pharma B.V. 77
Bellicum Pharmaceuticals, Inc. 78
Sigma-Tau Pharmaceuticals, Inc 79
Interprotein Corporation 80
EpiZyme, Inc. 81
NuCana BioMed Limited 82
Pfenex Inc. 83
Otsuka Holdings Co., Ltd. 84
Bexion Pharmaceuticals, LLC. 85
Karyopharm Therapeutics, Inc. 86
International Biotechnology Center Generium 87
Rhizen Pharmaceuticals SA 88
ARA Healthcare Pvt. Ltd. 89
Cantargia AB 90
Formula Pharmaceuticals, Inc. 91
AbbVie Inc. 92
Amgen Astellas BioPharma K.K. 93
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment 94
Assessment by Monotherapy Products 94
Assessment by Combination Products 95
Assessment by Target 96
Assessment by Mechanism of Action 101
Assessment by Route of Administration 107
Assessment by Molecule Type 109
Drug Profiles 112
ponatinib - Drug Profile 112
calaspargase pegol - Drug Profile 114
StemEx - Drug Profile 115
blinatumomab - Drug Profile 117
asparaginase - Drug Profile 120
vincristine sulfate liposomal - Drug Profile 122
inotuzumab ozogamicin - Drug Profile 125
Recombinant asparaginase - Drug Profile 127
asparaginase - Drug Profile 128
SAR-3419 - Drug Profile 129
moxetumomab pasudotox - Drug Profile 131
brentuximab vedotin - Drug Profile 133
ponatinib - Drug Profile 138
ATIR - Drug Profile 140
forodesine hydrochloride - Drug Profile 141
MOR-208 - Drug Profile 143
epratuzumab - Drug Profile 144
CTL-019 - Drug Profile 149
Iodine I-131 Monoclonal Antibody BC8 + [cyclophosphamide] + [fludarabine phosphate] + [mycophenolate mofetil] + [tacrolimus] + Allogeneic Bone Marrow Transplantation + Radiation Therapy - Drug Profile 151
glasdegib - Drug Profile 152
FPI-01 - Drug Profile 154
veltuzumab - Drug Profile 156
ponatinib - Drug Profile 159
lonafarnib - Drug Profile 161
ruxolitinib phosphate - Drug Profile 163
OVI-123 - Drug Profile 167
rigosertib sodium - Drug Profile 168
CD19CAR/Virus Specific T Cells - Drug Profile 171
birinapant - Drug Profile 172
BPX-501 - Drug Profile 174
Allogeneic CD19CAR-TCM cells - Drug Profile 176
Autologous CD19 CAR + EGFTt + T Cells - Drug Profile 177
DFP-10917 - Drug Profile 178
CD25/71 Allodepleted Donor T cells - Drug Profile 179
CD19 Transduced EBV-CTL - Drug Profile 180
Minor Histocompatibility Antigen - Drug Profile 181
ORY-1001 - Drug Profile 182
entinostat - Drug Profile 184
pevonedistat hydrochloride - Drug Profile 187
SGN-CD19A - Drug Profile 190
panobinostat - Drug Profile 191
4SC-202 - Drug Profile 197
AT-9283 - Drug Profile 199
SAR-650984 - Drug Profile 201
carfilzomib - Drug Profile 203
everolimus - Drug Profile 205
asparaginase - Drug Profile 210
ganetespib - Drug Profile 212
TH-302 - Drug Profile 216
(cytarabine + daunorubicin) - Drug Profile 223
quizartinib - Drug Profile 225
briciclib sodium - Drug Profile 227
ciclopirox olamine - Drug Profile 228
Combotox - Drug Profile 229
PF-03084014 - Drug Profile 230
BP-100-1.01 - Drug Profile 231
rebastinib tosylate - Drug Profile 233
GNKG-168 - Drug Profile 235
ilorasertib - Drug Profile 237
OPB-51602 - Drug Profile 239
BMS-906024 - Drug Profile 240
Anti-CD19-CAR-Transduced T Cells - Drug Profile 241
KPT-330 - Drug Profile 242
EPZ-5676 - Drug Profile 244
TGR-1202 - Drug Profile 245
Asparec - Drug Profile 246
SyB-0702 - Drug Profile 248
MD-707 - Drug Profile 249
serdemetan - Drug Profile 250
CBS-9106 - Drug Profile 252
Aurora + FLT3 Kinase Programme - Drug Profile 254
ARABS-1 - Drug Profile 255
IPC-003 - Drug Profile 256
Interleukin-1 Receptor Associated Protein Targeting Antibody - Drug Profile 257
Lenaldekar - Drug Profile 258
BXQ-350 - Drug Profile 259
Mastermind Coactivator Protein Derived Stapled Peptides - Drug Profile 261
BLyS-Gelonin Fusion Toxin - Drug Profile 262
PRT-060318 - Drug Profile 263
UNC-569 - Drug Profile 264
Small Molecule to Inhibit Mer Receptor Tyrosine Kinase for Oncology - Drug Profile 266
Mer Antibody - Drug Profile 268
Small molecules for Oncology - Drug Profile 269
GNR-022 - Drug Profile 270
MSK-777 - Drug Profile 271
CB-839 - Drug Profile 273
NUC-5435 - Drug Profile 274
pegaspargase biosimilar - Drug Profile 275
Drugs to Inhibit Gamma-Secretase for Acute Lymphocytic Leukemia - Drug Profile 276
BMS-871 - Drug Profile 277
KM-101 - Drug Profile 278
ABT-737 - Drug Profile 279
Tyrosine Kinase2 Program - Drug Profile 281
P2Y8 Antagonist for Acute Lymphoblastic Leukemia - Drug Profile 282
Turbostatin-1 - Drug Profile 283
Turbostatin-2 - Drug Profile 284
Turbostatin-3 - Drug Profile 285
Turbostatin-4 - Drug Profile 286
Drugs Targeting Tyrosine Kinase 2 - Drug Profile 287
Small Molecules to Inhibit JAK for Oncology and Hematological Disorders - Drug Profile 288
POL-5551 - Drug Profile 289
CRLF-2 Inhibitors - Drug Profile 291
KM-201 - Drug Profile 292
Asparec - Drug Profile 293
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Recent Pipeline Updates 295
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects 413
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products 414
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones 415
Featured News & Press Releases 415
Appendix 428
Methodology 428
Coverage 428
Secondary Research 428
Primary Research 428
Expert Panel Validation 428
Contact Us 429
Disclaimer 429
List of Tables
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2014 19
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H1 2014 20
Number of Products under Development by Companies, H1 2014 22
Number of Products under Development by Companies, H1 2014 (Contd..1) 23
Number of Products under Development by Companies, H1 2014 (Contd..2) 24
Number of Products under Development by Companies, H1 2014 (Contd..3) 25
Number of Products under Development by Companies, H1 2014 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Comparative Analysis by Late Stage Development, H1 2014 29
Comparative Analysis by Clinical Stage Development, H1 2014 30
Comparative Analysis by Early Stage Development, H1 2014 31
Comparative Analysis by Unknown Stage Development, H1 2014 32
Products under Development by Companies, H1 2014 33
Products under Development by Companies, H1 2014 (Contd..1) 34
Products under Development by Companies, H1 2014 (Contd..2) 35
Products under Development by Companies, H1 2014 (Contd..3) 36
Products under Development by Companies, H1 2014 (Contd..4) 37
Products under Investigation by Universities/Institutes, H1 2014 38
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2014 39
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Johnson & Johnson, H1 2014 40
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sanofi, H1 2014 41
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by GlaxoSmithKline plc, H1 2014 42
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H1 2014 43
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by MedImmune, LLC, H1 2014 44
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by medac GmbH, H1 2014 45
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Merck & Co., Inc., H1 2014 46
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gamida Cell Ltd., H1 2014 47
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H1 2014 48
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 49
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Novartis AG, H1 2014 50
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfizer Inc., H1 2014 51
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 52
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 53
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Incyte Corporation, H1 2014 54
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H1 2014 55
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Immunomedics, Inc., H1 2014 56
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2014 57
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoVista Innovative Therapies, Inc., H1 2014 58
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jazz Pharmaceuticals plc, H1 2014 59
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 60
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Mundipharma International Limited, H1 2014 61
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by MorphoSys AG, H1 2014 62
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 63
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Synta Pharmaceuticals Corp., H1 2014 64
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sareum Holdings plc, H1 2014 65
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by SymBio Pharmaceuticals Limited, H1 2014 66
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oryzon Genomics S.A., H1 2014 67
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 68
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ambit Biosciences Corporation, H1 2014 69
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Abiogen Pharma S.p.A., H1 2014 70
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ERYtech Pharma, H1 2014 71
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celator Pharmaceuticals, Inc., H1 2014 72
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Aileron Therapeutics, Inc., H1 2014 73
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by TetraLogic Pharmaceuticals., H1 2014 74
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CanBas Co., Ltd., H1 2014 75
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2014 76
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Onconova Therapeutics, Inc., H1 2014 77
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Effimune SAS, H1 2014 78
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kainos Medicine, Inc., H1 2014 79
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Polyphor Ltd., H1 2014 80
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Syndax Pharmaceuticals, Inc., H1 2014 81
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Omeros Corporation, H1 2014 82
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by SBI Biotech Co., Ltd., H1 2014 83
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kiadis Pharma B.V., H1 2014 84
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2014 85
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H1 2014 86
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Interprotein Corporation, H1 2014 87
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by EpiZyme, Inc., H1 2014 88
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NuCana BioMed Limited, H1 2014 89
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfenex Inc., H1 2014 90
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 91
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bexion Pharmaceuticals, LLC., H1 2014 92
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 93
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by International Biotechnology Center Generium, H1 2014 94
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 95
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ARA Healthcare Pvt. Ltd., H1 2014 96
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cantargia AB, H1 2014 97
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H1 2014 98
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc., H1 2014 99
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 100
Assessment by Monotherapy Products, H1 2014 101
Assessment by Combination Products, H1 2014 102
Number of Products by Stage and Target, H1 2014 105
Number of Products by Stage and Mechanism of Action, H1 2014 110
Number of Products by Stage and Route of Administration, H1 2014 115
Number of Products by Stage and Molecule Type, H1 2014 118
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics - Recent Pipeline Updates, H1 2014 302
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H1 2014 420
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, H1 2014 421
List of Figures
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2014 19
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H1 2014 20
Number of Products under Development by Companies, H1 2014 21
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Comparative Analysis by Late Stage Development, H1 2014 29
Comparative Analysis by Clinical Stage Development, H1 2014 30
Comparative Analysis by Early Stage Products, H1 2014 31
Assessment by Monotherapy Products, H1 2014 101
Assessment by Combination Products, H1 2014 102
Number of Products by Top 10 Target, H1 2014 103
Number of Products by Stage and Top 10 Target, H1 2014 104
Number of Products by Top 10 Mechanism of Action, H1 2014 108
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 109
Number of Products by Top 10 Route of Administration, H1 2014 114
Number of Products by Stage and Top 10 Route of Administration, H1 2014 115
Number of Products by Top 10 Molecule Type, H1 2014 116
Number of Products by Stage and Top 10 Molecule Type, H1 2014 117
